GRAIL, Inc. (GRAL) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $60.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 17%; Below-average business quality; Rich valuation.
GRAIL is a commercial-stage healthcare company selling Galleri, a blood test that screens for cancer signals from 50+ cancer types; filed a PMA with FDA in January 2026 and sold 475,000+ commercial tests through Dec 2025. Revenue comes almost entirely from Galleri test sales;... Read more
Sell if holding. Engine safety override at $60.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 17%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 58. Score 4.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — GRAIL, Inc.
Latest news
- TD Cowen Maintains Buy on GRAIL, Raises Price Target to $69 — benzinga May 6, 2026 positive
- Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $56 — benzinga May 6, 2026 positive
- GRAIL Q1 EPS $(2.29) Beats $(2.70) Estimate, Sales $39.832M Beat $38.881M Estimate — benzinga May 5, 2026 positive
- Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral
- GRAIL To Reveal New Data From NHS-Galleri And PATHFINDER 2 At 2026 ASCO Annual Meeting — benzinga Apr 21, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductGalleri10-K Item 1A: 'A substantial majority of our revenue is generated from sales of Galleri and we are highly dependent on it for our success'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Volatile — 6.2% daily ATR makes tight stops impractical. Position-size conservatively.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -253.2%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $60.00: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 17%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 58. Prior stop was $55.47. Score 4.6/10, moderate confidence.
Take-profit target: $63.39 (+6.3% upside). Prior stop was $55.47. Stop-loss: $55.47.
Concentration risk — Product: Galleri; Target reached (-2.5% upside); Quality below floor (2.9 < 4.0).
GRAIL, Inc. trades at a P/E of N/A (forward -6.5). TrendMatrix value score: 2.4/10. Verdict: Sell.
14 analysts cover GRAL with a consensus score of 3.9/5. Average price target: $67.
What does GRAIL, Inc. do?GRAIL is a commercial-stage healthcare company selling Galleri, a blood test that screens for cancer signals from 50+...
GRAIL is a commercial-stage healthcare company selling Galleri, a blood test that screens for cancer signals from 50+ cancer types; filed a PMA with FDA in January 2026 and sold 475,000+ commercial tests through Dec 2025. Revenue comes almost entirely from Galleri test sales; net loss was $408.4M in 2025 with $10.2B accumulated deficit largely from Illumina acquisition impairments.